ORBIMED ADVISORS LLC sold KROS

November 21, 2025 · Form 4 insider transaction

ORBIMED ADVISORS LLC sold 140,057 shares of Keros Therapeutics, Inc. at $17.75 per share, a transaction worth $2.49M. The trade was recorded as disposition to the issuer and disclosed on an SEC Form 4, filed 27 days after the transaction.

Direction
Disposed (sell-side)
Shares
140,057
Price
$17.75
Total value
$2.49M
Role
SecurityCommon Stock
Transaction codeD: Disposition to the issuer
Transaction dateNovember 21, 2025
Filing dateDecember 18, 2025
Shares owned after759,155
OwnershipIndirect
10b5-1 planNo
AmendedNo

Footnotes

Disposed of in connection with the Issuer's completion of a cash tender offer.; These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("OrbiMed GP") is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of OrbiMed GP. By virtue of such relationships, OrbiMed GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII.; This report on Form 4 is jointly filed by OrbiMed Advisors, OrbiMed GP, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

View the original Form 4 on SEC EDGAR